Related Articles
Labcorp to acquire Invitae’s assets for $239M
William Blair analyst Andrew Brackmann said Labcorp is being aggressive in its M&A strategy, after announcing last month it would buy several of Bioreference Health’s testing businesses.
Leanne Hainsby (@leannehainsby) • Instagram photos and videos
71K likes, 1,388 comments – leannehainsby on April 21, 2024: “So proud of us. Today, we completed the 2024 London Marathon 🎉🙌🏻 What’s even more…
Headache Journal (@headachejournal) • Instagram photos and videos
3 likes, 0 comments – headachejournal on April 25, 2024: “Screen exposure is often reported as a headache trigger, though there is no current consensus…
American Academy of Neurology (@aanbrain) • Instagram reel
31 likes, 0 comments – aanbrain on April 24, 2024: “Thank you for making this year’s Annual Meeting unforgettable! 🌟 We welcomed 14,000 attendees…
American Academy of Ophthalmology (@aaojournal) • Instagram photos and videos
17 Followers, 7 Following, 1 Posts – See Instagram photos and videos from American Academy of Ophthalmology (@aaojournal)
MRC GIDA (@mrc_outbreak) • Instagram photos and videos
152 Followers, 125 Following, 104 Posts – See Instagram photos and videos from MRC GIDA (@mrc_outbreak)
Ohio State Gyn-Onc Fellowship (@osu_gynonc_fellowship) • Instagram photo
52 likes, 2 comments – osu_gynonc_fellowship on April 22, 2024: “Congratulations to our PGY6 fellows Molly and Polly on a successful thesis defense tonight. Also…
MRC GIDA (@mrc_outbreak) • Instagram photos and videos
152 Followers, 125 Following, 104 Posts – See Instagram photos and videos from MRC GIDA (@mrc_outbreak)
MedPage Today | Medical News (@medpage) • Instagram photos and videos
6,596 Followers, 639 Following, 2,517 Posts – See Instagram photos and videos from MedPage Today | Medical News (@medpage)
ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.